| Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults. | 33179245 | PMC8092672 | Journal | 2020 | 10.1002/14651858.CD013393.pub2 | MTOPS | 21689 | Secondary Research |
| An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. | 15380054 | | Journal | 2004 | | MTOPS | | Contributing Study |
| Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. | 16516013 | | Journal | 2006 | 10.1016/S0022-5347(05)00708-1 | MTOPS | | Contributing Study |
| Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. | 16406915 | | Journal | 2006 | 10.1016/S0022-5347(05)00041-8 | MTOPS | | Contributing Study |
| Cross-sectional and longitudinal associations of sexual function with lower urinary tract symptoms in men with benign prostatic hyperplasia. | 25150638 | | Journal | 2015 | 10.1016/j.juro.2014.08.086 | MTOPS | 3508 | Secondary Research |
| EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). | 15474261 | | Journal | 2004 | 10.1016/j.eururo.2004.07.016 | MTOPS | | Contributing Study |
| Genomic analysis of benign prostatic hyperplasia implicates cellular relandscaping in disease pathogenesis | 31094703 | PMC6629137 | Journal | 2019 | 10.1172/jci.insight.129749 | MTOPS | 21099 | Secondary Research |
| Inhibition of the CXCL12/CXCR4 axis prevents peri-urethral collagen accumulation and lower urinary tract dysfunction in vivo | 30811623 | PMC7269149 | Journal | 2019 | 10.1002/pros.23781 | MTOPS | 20150, 20877, 21725 | Secondary Research |
| Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. | 23357210 | | Journal | 2013 | 10.1016/j.juro.2013.01.061 | MTOPS | | Contributing Study |
| Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. | 21334655 | PMC3677556 | Journal | 2011 | 10.1016/j.juro.2010.11.060 | MTOPS | | Contributing Study |
| MTOPS: conclusions about invasive therapy for BPH should be interpreted with caution. | 15541145 | | Journal | 2004 | 10.1111/j.1464-410X.2004.05213_2.x | MTOPS | | Contributing Study |
| Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. | 16129387 | | Journal | 2005 | 10.1016/s1543-5946(05)00031-0 | MTOPS | | Contributing Study |
| Preservation of Sexual Function 5 Years After Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia | 34731779 | PMC8766265 | Journal | 2021 | 10.1016/j.esxm.2021.100454 | MTOPS | 22013 | Secondary Research |
| Prostate Biopsy Markers of Inflammation are Associated with Risk of Clinical Progression of Benign Prostatic Hyperplasia: Findings from the MTOPS Study. | 25828974 | | Journal | 2015 | 10.1016/j.juro.2015.03.103 | MTOPS | 1368 | Secondary Research |
| Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study. | 31188728 | PMC7339116 | Journal | 2019 | 10.1097/JU.0000000000000385 | MTOPS | 20150, 20877, 21725 | Secondary Research |
| Recruitment for a clinical trial of drug treatment for benign prostatic hyperplasia. | 11796283 | | Journal | 2002 | 10.1016/s0090-4295(01)01454-6 | MTOPS | | Contributing Study |
| Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. | 21554128 | PMC3155098 | Journal | 2011 | 10.1089/acm.2010.0300 | MTOPS | | Contributing Study |
| Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. | 27375287 | PMC5841614 | Journal | 2016 | 10.1093/ije/dyw118 | SISTEr, DPP, FAVORIT, HEMO, MTOPS, ATN, HALT-C | 6371, 6372, 6830, 8068, 8148, 8168, 8169, 8170 | Secondary Research |
| SRD5A2 Expression Is A Predictor Of Response To Finasteride In The MTOPS Trial | | | Journal | 2023 | 10.1097/JU.0000000000003219.05 | MTOPS | 22990 | Secondary Research |
| Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. | 12689743 | | Journal | 2003 | 10.1016/s0197-2456(02)00263-5 | MTOPS | | Contributing Study |
| The IL-4/IL-13 signaling axis promotes prostatic fibrosis | 36201508 | PMC9536598 | Journal | 2022 | 10.1371/journal.pone.0275064 | MTOPS | 20877, 21725 | Secondary Research |
| The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. | 15705083 | | Journal | 2005 | 10.1111/j.1464-410X.2005.05342.x | MTOPS | | Contributing Study |
| The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. | 14681504 | | Journal | 2003 | 10.1056/NEJMoa030656 | MTOPS | | Contributing Study |
| The reduction of male lower urinary tracts symptoms is associated with a decreased risk of death | 37681541 | | Journal | 2023 | 10.1097/JU.0000000000003602 | MTOPS | 23674 | Secondary Research |
| The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. | 15260927 | | Journal | 2004 | 10.1007/s11934-004-0050-6 | MTOPS | | Contributing Study |
| Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS. | 15091044 | | Journal | 2004 | 10.1097/00042307-200401000-00004 | MTOPS | | Contributing Study |
| [Analysis of the scientific evidence of the combination therapy in benign prostatic hyperplasia]. | 16304902 | | Journal | 2005 | | MTOPS | | Contributing Study |
| [Drug therapy of benign prostatic hyperplasia. Is combination therapy with 5 alpha-reductase inhibitors and alpha-receptor blockers effective?]. | 12426860 | | Journal | 2002 | 10.1007/s00120-002-0229-8 | MTOPS | | Contributing Study |
